{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T17:27:55Z","timestamp":1784222875302,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,27]]},"DOI":"10.7759\/cureus.93373","type":"journal-article","created":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T04:00:41Z","timestamp":1759032041000},"source":"Crossref","is-referenced-by-count":2,"title":["Glucagon-Like Peptide-1 Receptor Agonists for Arthritis and Osteoarthritis"],"prefix":"10.7759","author":[{"given":"Abdulqadir  J","family":"Nashwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.03.013","article-title":"Treatment strategy for type 2 diabetes with obesity: focus on glucagon-like peptide-1 receptor agonists","volume":"39","author":"Ji Q","year":"2017","unstructured":"Ji Q. Treatment strategy for type 2 diabetes with obesity: focus on glucagon-like peptide-1 receptor agonists. Clin Ther. 2017, 39:1244-64. 10.1016\/j.clinthera.2017.03.013","journal-title":"Clin Ther"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12050420","article-title":"The sensory mechanisms of nutrient-induced GLP-1 secretion","volume":"12","author":"Hj\u00f8rne AP","year":"2022","unstructured":"Hj\u00f8rne AP, Modvig IM, Holst JJ. The sensory mechanisms of nutrient-induced GLP-1 secretion. Metabolites. 2022, 12:10.3390\/metabo12050420","journal-title":"Metabolites"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker DJ","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018, 27:740-56. 10.1016\/j.cmet.2018.03.001","journal-title":"Cell Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-05323-7","article-title":"Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts\u00a0analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis","volume":"12","author":"Meurot C","year":"2022","unstructured":"Meurot C, Martin C, Sudre L, et al.. Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts\u00a0analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis. Sci Rep. 2022, 12:1567. 10.1038\/s41598-022-05323-7","journal-title":"Sci Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3094642","article-title":"Anti-inflammatory effects of GLP-1-based therapies beyond glucose control","volume":"2016","author":"Lee YS","year":"2016","unstructured":"Lee YS, Jun HS. Anti-inflammatory effects of GLP-1-based therapies beyond glucose control. Mediators Inflamm. 2016, 2016:3094642. 10.1155\/2016\/3094642","journal-title":"Mediators Inflamm"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.glmedi.2024.100136","article-title":"The rising threat of counterfeit GLP-1 receptor agonists: implications for public health","volume":"3","author":"Rehman A","year":"2024","unstructured":"Rehman A, Nashwan AJ. The rising threat of counterfeit GLP-1 receptor agonists: implications for public health. J Med Surg Pub Health. 2024, 3:100136. 10.1016\/j.glmedi.2024.100136","journal-title":"J Med Surg Pub Health"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403664","article-title":"Once-weekly semaglutide in persons with obesity and knee osteoarthritis","volume":"391","author":"Bliddal H","year":"2024","unstructured":"Bliddal H, Bays H, Czernichow S, et al.. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N Engl J Med. 2024, 391:1573-83. 10.1056\/NEJMoa2403664","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40520-025-03017-4","article-title":"Comparative efficacy and safety of antidiabetic drugs for obese patients with knee osteoarthritis: a network meta-analysis of randomized controlled trials","volume":"37","author":"Jiang G","year":"2025","unstructured":"Jiang G, Yang X, Zhu G, Liu T. Comparative efficacy and safety of antidiabetic drugs for obese patients with knee osteoarthritis: a network meta-analysis of randomized controlled trials. Aging Clin Exp Res. 2025, 37:142. 10.1007\/s40520-025-03017-4","journal-title":"Aging Clin Exp Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223845","article-title":"Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort","volume":"82","author":"Zhu H","year":"2023","unstructured":"Zhu H, Zhou L, Wang Q, et al.. Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort. Ann Rheum Dis. 2023, 82:1218-26. 10.1136\/ard-2023-223845","journal-title":"Ann Rheum Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/art.42754","article-title":"Weight loss induced by antiobesity medications and all-cause mortality among patients with knee or hip osteoarthritis","volume":"76","author":"Wei J","year":"2024","unstructured":"Wei J, Hunter D, Lane NE, Wu J, Zeng C, Lei G, Zhang Y. Weight loss induced by antiobesity medications and all-cause mortality among patients with knee or hip osteoarthritis. Arthritis Rheumatol. 2024, 76:577-86. 10.1002\/art.42754","journal-title":"Arthritis Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/art.42996","article-title":"Weight loss after receiving anti-obesity medications and gout among individuals with overweight and obese: a population-based cohort study","volume":"77","author":"Wei J","year":"2025","unstructured":"Wei J, Wang Y, Dalbeth N, et al.. Weight loss after receiving anti-obesity medications and gout among individuals with overweight and obese: a population-based cohort study. Arthritis Rheumatol. 2025, 77:335-45. 10.1002\/art.42996","journal-title":"Arthritis Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-024-07640-6","article-title":"Liraglutide, a glucagon-like peptide-1 receptor agonist, ameliorates inflammation and apoptosis via inhibition of receptor for advanced glycation end products signaling in AGEs induced chondrocytes","volume":"25","author":"Zhang X","year":"2024","unstructured":"Zhang X, Jiang J, Xu J, Chen J, Gu Y, Wu G. Liraglutide, a glucagon-like peptide-1 receptor agonist, ameliorates inflammation and apoptosis via inhibition of receptor for advanced glycation end products signaling in AGEs induced chondrocytes. BMC Musculoskelet Disord. 2024, 25:601. 10.1186\/s12891-024-07640-6","journal-title":"BMC Musculoskelet Disord"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03542-9","article-title":"Author correction: mapping the effectiveness and risks of GLP-1 receptor agonists","volume":"31","author":"Xie Y","year":"2025","unstructured":"Xie Y, Choi T, Al-Aly Z. Author correction: mapping the effectiveness and risks of GLP-1 receptor agonists. Nat Med. 2025, 31:1038. 10.1038\/s41591-025-03542-9","journal-title":"Nat Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.11005\/jbm.2024.31.3.169","article-title":"Antidiabetic agents and bone quality: a focus on glycation end products and incretin pathway modulations","volume":"31","author":"Zaki MK","year":"2024","unstructured":"Zaki MK, Abed MN, Alassaf FA. Antidiabetic agents and bone quality: a focus on glycation end products and incretin pathway modulations. J Bone Metab. 2024, 31:169-81. 10.11005\/jbm.2024.31.3.169","journal-title":"J Bone Metab"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001949","article-title":"Glucagon-like peptide 1 receptor agonists in patients with inflammatory arthritis or psoriasis: a scoping review","volume":"30","author":"Karacabeyli D","year":"2024","unstructured":"Karacabeyli D, Lacaille D. Glucagon-like peptide 1 receptor agonists in patients with inflammatory arthritis or psoriasis: a scoping review. J Clin Rheumatol. 2024, 30:26-31. 10.1097\/RHU.0000000000001949","journal-title":"J Clin Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.70638","article-title":"Exploring glucagon-like peptide-1 receptor agonists usage among non-diabetic healthcare providers: a cross-sectional multi-country study","volume":"8","author":"Nashwan AJ","year":"2025","unstructured":"Nashwan AJ, Abukhadijah HJ, Karavadi V, et al.. Exploring glucagon-like peptide-1 receptor agonists usage among non-diabetic healthcare providers: a cross-sectional multi-country study. Health Sci Rep. 2025, 8:e70638. 10.1002\/hsr2.70638","journal-title":"Health Sci Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/phar.70005","article-title":"The potential role of GLP-1 receptor agonists in osteoarthritis","volume":"45","author":"Ryan M","year":"2025","unstructured":"Ryan M, Megyeri S, Nuffer W, Trujillo JM. The potential role of GLP-1 receptor agonists in osteoarthritis. Pharmacotherapy. 2025, 45:177-86. 10.1002\/phar.70005","journal-title":"Pharmacotherapy"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/413001-glucagon-like-peptide-1-receptor-agonists-for-arthritis-and-osteoarthritis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T04:00:47Z","timestamp":1759032047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/413001-glucagon-like-peptide-1-receptor-agonists-for-arthritis-and-osteoarthritis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,27]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.93373","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,27]]}}}